Modality
Gene Therapy
MOA
BCL-2i
Target
JAK1
Pathway
Complement
RA
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ Jul 2028
Phase 1Current
NCT03793711
648 pts·RA
2020-11→2028-07·Terminated
648 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-176mo agoBTD· RA
2028-07-042.3y awayPh2 Data· RA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Termina…
Catalysts
BTD
2025-09-17 · 6mo ago
RA
Ph2 Data
2028-07-04 · 2.3y away
RA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03793711 | Phase 1/2 | RA | Terminated | 648 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |